Allogene lays off 28% of staff to extend runway amid delays to CAR-T updates
Allogene Therapeutics is cutting back to stretch its cash runway into the second half of 2027, laying off 28% of its workforce and focusing its resources on getting two clinical programs to inflection points. The off-the-shelf CAR-T cell therapy specialist disclosed the changes alongside delays to two milestones.
Allogene Therapeutics is cutting back to stretch its cash runway into the second half of 2027, laying off 28% of its workforce and focusing its resources on getting two clinical programs to inflection points. The off-the-shelf CAR-T cell therapy specialist disclosed the changes alongside delays to two milestones.
